Omacor Wins
Approval In Norway
Omacor, produced by Pronova Biocare, Lysaker, Norway, has been approved in Norway for the treatment of post-infarct patients. The formulation is more than 90% omega 3 (84% EPA and DHA) and one capsule per day dosing enhances patient compliance. In clinical trials, side effects were few, transient and mild.